National Institute for Health and Care Excellence (NICE)
- Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis.
- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. This updates a previously published guideline summary.
- Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears.
- Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. This updates a previously published guideline summary.
No hay comentarios:
Publicar un comentario